ALNYLAM PHARMACEUTICALS INC (ALNY)
US02043Q1076 - Common Stock
| MRQ (2023-9-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 1.03B | 866.40M | 820.00M | 496.60M | 547.20M | |||
| Marketable Securities | 1.37B | 1.33B | 1.62B | 1.38B | 989.00M | |||
| Receivables | 325.40M | 238.00M | 198.60M | 602.40M | 43.00M | |||
| Inventories | 95.80M | 129.00M | 86.40M | 75.20M | 56.30M | |||
| Other Current Assets | 158.00M | 132.90M | 88.10M | 62.80M | 80.30M | |||
| Total Current Assets | 2.99B | 2.69B | 2.81B | 2.61B | 1.72B | |||
| Non-Current Assets | ||||||||
| PPE Net | 729.10M | 738.60M | 733.60M | 706.50M | 646.40M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 124.50M | 115.50M | 101.10M | 85.80M | 32.90M | |||
| Total Non-Current Assets | 853.60M | 854.20M | 834.70M | 792.30M | 679.20M | |||
| TOTAL ASSETS | 3.84B | 3.55B | 3.64B | 3.41B | 2.40B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 754.60M | 587.40M | 435.70M | 392.80M | 224.90M | |||
| Accounts Payable | 73.80M | 98.10M | 73.40M | 52.00M | 49.90M | |||
| Other Current Liabilities | 121.30M | 82.40M | 186.60M | 140.50M | 77.80M | |||
| Total Current Liabilities | 949.80M | 767.90M | 695.70M | 585.30M | 352.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 1.02B | 1.02B | 675.70M | 191.30M | 0.00 | |||
| Other Non-Current Liabilities | 2.04B | 1.92B | 1.68B | 1.61B | 603.80M | |||
| Total Non-Current Liabilities | 3.06B | 2.94B | 2.36B | 1.81B | 603.80M | |||
| TOTAL LIABILITIES | 4.00B | 3.70B | 3.06B | 2.39B | 956.40M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -6.87B | -6.57B | -5.44B | -4.59B | -3.73B | |||
| Additional Paid In Capital | 6.74B | 6.45B | 6.06B | 5.64B | 5.20B | |||
| Common Shares | 1.30M | 1.20M | 1.20M | 1.20M | 1.10M | |||
| Other Shareholders' Equity | 5.90M | -2.40M | 1.20M | -11.20M | -3.90M | |||
| Shares Outstanding | 125.50M | 123.90M | 120.20M | 116.40M | 112.20M | |||
| Tangible Book Value per Share | -1.32 | -1.28 | 4.89 | 8.73 | 12.82 | |||
| Total Shareholders' Equity | -165.90M | -158.20M | 588.20M | 1.02B | 1.44B | |||
| TOTAL LIABILITIES AND EQUITY | 3.84B | 3.55B | 3.64B | 3.41B | 2.40B | |||
| Statistics | ||||||||
| Debt/Equity | -6.15 | -6.43 | 1.15 | 0.19 | N/A | |||
| Current Ratio | 3.14 | 3.51 | 4.04 | 4.47 | 4.87 | |||
| Return On Assets (ROA) | -13.28% | -31.90% | -23.41% | -25.19% | -37.00% | |||
| Return On Equity (ROE) | N/A | N/A | -144.98% | -84.46% | -61.59% | |||
All data in USD